...
首页> 外文期刊>Asian journal of andrology >The preparation and application of N-terminal 57 amino acid protein of the follicle-stimulating hormone receptor as a candidate male contraceptive vaccine
【24h】

The preparation and application of N-terminal 57 amino acid protein of the follicle-stimulating hormone receptor as a candidate male contraceptive vaccine

机译:促卵泡激素受体N末端57氨基酸蛋白作为男性避孕药的制备及应用

获取原文
           

摘要

Follicle-stimulating hormone receptor (FSHR), which is expressed only on Sertoli cells and plays a key role in spermatogenesis, has been paid attention for its potential in male contraception vaccine research and development. This study introduces a method for the preparation and purification of human FSHR 57-amino acid protein (FSHR-57aa) as well as determination of its immunogenicity and antifertility effect. A recombinant pET-28a(+)-FSHR-57aa plasmid was constructed and expressed in Escherichia coli strain BL21 Star TM (DE3) and the FSHR-57aa protein was separated and collected by cutting the gel and recovering activity by efficient refolding dialysis. The protein was identified by Western blot and high-performance liquid chromatography analysis with a band of nearly 7 kDa and a purity of 97.4%. Male monkeys were immunized with rhFSHR-57aa protein and a gradual rising of specific serum IgG antibody was found which reached a plateau on day 112 (16 weeks) after the first immunization. After mating of one male with three female monkeys, the pregnancy rate of those mated with males immunized against FSHR-57aa was significantly decreased while the serum hormone levels of testosterone and estradiol were not disturbed in the control or the FSHR-57aa groups. By evaluating pathological changes in testicular histology, we found that the blood-testis barrier remained intact, in spite of some small damage to Sertoli cells. In conclusion, our study demonstrates that the rhFSHR-57aa protein might be a feasible male contraceptive which could affect sperm production without disturbing hormone levels.
机译:促卵泡激素受体(FSHR)仅在支持细胞上表达,在精子发生中起关键作用,由于其在男性避孕疫苗研究和开发中的潜力而受到关注。本研究介绍了一种制备和纯化人FSHR 57-氨基酸蛋白(FSHR-57aa)的方法,以及其免疫原性和抗生育作用的测定方法。构建了重组pET-28a(+)-FSHR-57aa质粒并在大肠杆菌BL21 Star TM (DE3)中表达,并通过切割凝胶和分离回收FSHR-57aa蛋白。通过有效的折叠透析进行活性。通过蛋白质印迹和高效液相色谱分析鉴定出该蛋白质,其条带接近7 kDa,纯度为97.4%。用rhFSHR-57aa蛋白免疫雄性猴子,发现特异性血清IgG抗体逐渐升高,首次免疫后第112天(16周)达到稳定水平。一只雄性与三只雌性猴子交配后,与雄性交配过FSHR-57aa免疫的那些的怀孕率显着降低,而对照组或FSHR-57aa组的睾丸激素和雌二醇的血清激素水平不受干扰。通过评估睾丸组织学的病理变化,我们发现尽管睾丸支持细胞有一些小损伤,但血-睾丸屏障仍然完好无损。总之,我们的研究表明,rhFSHR-57aa蛋白可能是可行的男性避孕药,它可以影响精子产生而不会干扰激素水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号